Results 41 to 50 of about 648 (164)

Women's Health in Multiple Sclerosis: A Scoping Review [PDF]

, 2022
Multiple sclerosis; Pregnancy; Women's healthEsclerosis múltiple; Embarazo; Salud de la mujerEsclerosi múltiple; Embaràs; Salut de la donaBackground: Women with multiple sclerosis (MS) may face challenges related to managing reproduction, pregnancy, and ...
Amato, M. P.
core   +4 more sources

Comparative pharmacokinetics and bioavailability of monomethyl fumarate following a single oral dose of Bafiertam® (monomethyl fumarate) versus Vumerity® (diroximel fumarate)

Multiple Sclerosis and Related Disorders, 2023
Bafiertam® (monomethyl fumarate [MMF]) and Vumerity® (diroximel fumarate [DRF]) are two FDA approved drug products for the treatment of relapsing forms of multiple sclerosis (MS) to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Franck S, Rousseau, Laurene, Wang, Tiffany N, Sprague, Thomas W, Lategan, Regina R, Berkovich   +4 more
openaire   +2 more sources

Repurposing Fumaric Acid Esters to Treat Conditions of Oxidative Stress and Inflammation: A Promising Emerging Approach with Broad Potential [PDF]

, 2020
The medicinal benefit of salts of fumaric acid and its esters (FAE), known as fumarates (mono and dimethyl fumarate), was realized many years ago. Early on, FAE were derived from plants and mushrooms (e.g., Fumaria officinalis, Boletus fomentarius var ...
Jadeja, Ravirajsinh N., Martin, Pamela M., Powell, Folami L.   +2 more
core   +1 more source

The development of novel combinations therapies for the treatment of triple negative breast cancer [PDF]

, 2023
Introduction: Cancer has one of the highest mortality rates in humans, second only to heart disease. In 2018 there was an estimated 9.6 million deaths due to cancer.
Gardiner, Hannah
core   +2 more sources

Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis [PDF]

, 2021
Importance: Emergence of SARS-CoV-2 causing COVID-19 prompted the need to gather information on clinical outcomes and risk factors associated with morbidity and mortality in patients with multiple sclerosis (MS) and concomitant SARS-CoV-2 infections ...
Bebo, Bruce, Costello, Kathleen, Cross, Anne H, Cutter, Gary R, Fox, Robert J, Halper, June, Kanellis, Pamela, Li, David K B, Newsome, Scott D, Rammohan, Kottil, Salter, Amber   +10 more
core   +2 more sources

Exploring the use of dimethyl fumarate as microglia modulator for neurodegenerative diseases treatment [PDF]

, 2020
The maintenance of redox homeostasis in the brain is critical for the prevention of the development of neurodegenerative diseases. Drugs acting on brain redox balance can be promising for the treatment of neurodegeneration.
Baiocco P., Cortese B., Di Angelantonio S., Parisi G., Rosito M., Testi C.   +5 more
core   +1 more source

Disease‐modifying therapies in multiple sclerosis: A focused review of rituximab

Basic &Clinical Pharmacology &Toxicology, Volume 133, Issue 5, Page 550-564, November 2023., 2023
Abstract Background Treatment for multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system, has changed drastically in the last 30 years. Several different disease‐modifying therapies are now available, with off‐label use of the B‐cell‐depleting antibody rituximab becoming an increasingly popular choice, as more and more ...
Peter Alping
wiley   +1 more source

Do clinical trials prepare to fail by failing to prepare? An examination of MS trials and recommendations for patient-reported outcome measure selection [PDF]

, 2023
BACKGROUND: Many clinical trials use patient-reported outcome (PRO) measures, which can influence treatment decision-making, drug approval and label claims.
Burke, L, Chitnis, T, Hobart, J, King, M, Lloyd, A, Oh, J, Vandercappellen, J, Vo, P   +7 more
core   +2 more sources

Repurposing MS Immunotherapies for CIDP and Other Autoimmune Neuropathies: Unfulfilled Promise or Efficient Strategy? [PDF]

, 2023
Despite advances in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and other common autoimmune neuropathies (AN), still-many patients with these diseases do not respond satisfactorily to the available treatments ...
Dalakas, Marinos, Kohle, Felix, Lehmann, Helmar C   +2 more
core   +2 more sources

Treatment of relapsing multiple sclerosis in Hungary – consensus recommendation from the Hungarian neuroimmunology society [PDF]

, 2023
Multiple sclerosis (MS) may impact quality of life, careers and family plans of the affected individuals. The current treatments with disease modifying therapies aim to prevent people with MS (pwMS) from disability accumulation and progression. Different
Bíró Zita, Csepany Tünde, Deme István, Illés Zsolt, Imre Piroska, Jakab Gábor, Jobbágy Zita, Lovas Gábor, Mezei Zsolt, Mike Andrea, Mátyás Klotild, Rajda Cecília, Rum Gábor, Rózsa Csilla, Simó Magdolna, Trauninger Anita, Ács Péter   +16 more
core   +4 more sources